This clinical trial is focused on studying a condition known as liver cirrhosis, which is a disease where the liver becomes scarred and its function is impaired. The study specifically looks at liver cirrhosis with features of portal hypertension, a complication where there is increased blood pressure in the vein that carries blood from the digestive organs to the liver. The trial is investigating the effects of two medications, Zibotentan and Dapagliflozin, both individually and in combination, compared to a placebo. Zibotentan, also known by its code name ZD4054, is taken as a hard capsule, while Dapagliflozin is administered as a film-coated tablet.

The purpose of the study is to assess how these medications can affect the condition of patients with liver cirrhosis and portal hypertension. Participants will be randomly assigned to receive either the combination of Zibotentan and Dapagliflozin, Dapagliflozin alone, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will be conducted over a period of 16 weeks, during which the participants’ health and response to the treatment will be closely monitored.

Throughout the study, the main focus will be on measuring changes in a specific pressure in the liver, known as hepatic venous pressure gradient (HVPG), from the start of the study to the end. This measurement helps to understand the severity of portal hypertension and the effectiveness of the treatment. The study will also look at other health indicators, such as body weight and blood pressure, to evaluate the overall safety and tolerability of the medications. Participants will be required to take the medications orally, and their progress will be assessed at regular intervals to gather comprehensive data on the treatment’s impact.